Human preterm and term parturition is associated with inflammatory cascades in the uteroplacental unit. Activation of the complement cascade releases potent proinflammatory mediators, including the anaphylatoxin C5a, which exerts its biological effects through its receptors, C5AR (also known as CD88) and C5L2, official symbol GPR77. To date, there are few data available on the role of C5a and CD88 in human pregnancy, so the aim of this study was to determine the effect of C5a and CD88 on some key inflammatory pathways involved in human parturition. Placental tissue samples were obtained from normal pregnancies at the time of Cesarean section. Human placental and fetal membranes were incubated in the absence (basal control) or presence of 0.5 lg/ml (;60 nM) human recombinant C5a for 24 h. Concentrations of proinflammatory cytokines, prostaglandins, and 8-isoprostane (a marker of oxidative stress) were quantified by ELISA and secretory matrix metalloproteinases (MMPs) activity by zymography. NFKB DNA binding activity and NFKBIA (IkappaB-alpha; inhibitor of NFKB) protein degradation were analyzed by ELISA and Western blotting, respectively. In the presence of C5a, proinflammatory cytokines (IL6 and IL8), cyclooxygenase (COX)-2; official symbol PTGS2) expression, and subsequent prostaglandin (PGE 2 and PGF 2alpha ), MMP9 enzyme production, and NFKB DNA activation were all significantly increased. The C5a-induced prolabor responses were significantly reduced by treatment with the selective CD88 antagonist PMX53 and the NFKB inhibitor BAY 11-7082. We conclude that C5a upregulates prolabor mediators in human gestational tissues via CD88-mediated NFKB activation.
INTRODUCTION
To provide the best possible start to life and improve health outcomes for both mother and baby, a critical issue that must be resolved is how spontaneous-onset labor is initiated. This is of clinical significance, as preterm labor and delivery is one of the most important complications contributing to poor pregnancy and to neonatal outcome [1] . The pathogenesis of spontaneous-onset preterm labor is not well understood; however, a critical role for cytokines, prostaglandins, extracellular matrix (ECM) remodeling, reactive oxygen species (ROS), and nuclear factor-jB (NFKB) in the terminal processes of term labor and in infection-associated preterm labor has been demonstrated [2] [3] [4] [5] [6] [7] [8] [9] . In recent times, dysregulation of the complement system has been linked to human labor [10] and infection-associated preterm birth [10] .
The complement cascade is activated by via four major pathways: the classical (C1qrs, C2, C4), the alternative pathway (C3, factor B, properdin), the lectin pathway (mannan-binding lectin), and the extrinsic pathway (which cleaves C3 and C5 directly through serine proteases) [11, 12] . Activation of the complement system induces the release of potent proinflammatory mediators, including the anaphylatoxins; the complement split products C3a, C4a and C5a. Considered the most potent of the anaphylatoxins, C5a is generated following the action of enzymes with convertase activity on C5 [13] . The actions of C5a via its classical G protein receptor (C5AR/CD88) on various cell types results in the release of numerous proinflammatory cytokines and chemokines, including IL6, IL8, and TNF (TNF-a) [14] . As such, C5a has been implicated in pathogenesis of a number of inflammatory diseases, including asthma [15] , cancer [16] , and rheumatoid arthritis [17] . C5a exerts its major biological effects by binding to and activating CD88. Although CD88 is widely distributed in multiple cell types and regions in the body [18] [19] [20] [21] , its expression and localization in human gestational tissues has not yet been reported.
Normal human pregnancy is characterized by a significant increase in C5a in the maternal circulation, an increase that does not change with increasing gestational age [22, 23] . However, the maternal plasma concentration of anaphylatoxin C5a is increased in women with preterm labor and intraamniotic infection [10] . In nongestational tissues, C5a has been shown to induce inflammation [14] , and the pharmacological targeting of anaphylatoxin receptors suppresses inflammation [24] . Given that human labor is characterized by inflammation of the intrauterine compartment [2-9], C5a and/or CD88 may regulate the terminal processes of human labor and delivery. The aim of this study was to determine the effect of C5a, in the absence or presence of the selective CD88 antagonist PMX53 [25] , on proinflammatory cytokines (IL6 and IL8), phospholipid metabolism (cyclooxygenase [COX] expression and subsequent prostaglandin release), proteases (MMP2 and MMP9 activity), and oxidative stress (8-isoprostane, a marker of lipid peroxidation) in human gestational tissues. In nongestational tissues, C5a has been shown to act via activation of a number of signaling pathways, including NFKB [26] [27] [28] . Thus, the role of NFKB involved in this regulation was also investigated.
Recent studies have shown that there is cross talk between toll-like receptors (TLRs) and C5a in response to invading microorganisms [14, 29] . LPS is a TLR4 ligand and is likely to be a factor stimulating the production of cytokines, prostaglandins, and oxidative stress in the context of infectionmediated preterm labor. The effect of LPS priming of cells for subsequent C5a -mediated activation via their respective receptors is now acknowledged [14] . Because of this, our study has also examined the relationship between LPSstimulated cells and its consequences on C5a-mediated processes. To elucidate this, we have also used a specific CD88 antagonist to determine the contribution of C5a receptor activation in LPS-stimulated cellular events. Furthermore, the effect of C5a on LPS-induced prolabor mediators was also investigated.
MATERIALS AND METHODS

Sample Collection
The Research Ethics Committee of Mercy Hospital for Women approved this study. Written, informed consent was obtained from all women participating in this study. Human placentae with attached fetal membranes were obtained from women who delivered healthy, singleton infants at term (!37 wk gestation) elective Cesarean section (indications for Cesarean section were breech presentation and/or previous Cesarean section) in the absence of labor.
Tissue Explants
Placental tissue was blunt dissected to remove visible connective tissue and calcium deposits. Fetal membranes (combined amnion and choriodecidua) were obtained approximately 2 cm from the periplacental edge and dissected into ;2.5-cm 2 squares. Tissue fragments were placed in DMEM (supplemented with 100 /ml penicillin G and 100 lg/ml streptomycin) and equilibrated for 1 h at 8% O 2 and 5% CO 2 at 378C. Tissues were then transferred to 24-well tissue culture plates (100 mg wet weight/ml) and treated with stimuli as detailed below. An initial dose-response experiment was performed whereby fetal membranes were incubated in the absence or presence of 0.1, 0.25, and 0.5 lg/ ml human recombinant C5a (R&D Systems). As shown in Figure 1 , 0.5 lg/ml (equating to ;60nM) was the most efficacious concentration of C5a in causing cytokine release from fetal membranes. All subsequent experiments were thus performed using 0.5 lg/ml C5a. Each experiment was performed using a minimum of four patients with two replicates per treatment. We first determined the effect of C5a on prolabor mediators in human gestational tissues. For these experiments, human placenta and fetal membranes were incubated in the absence or presence of C5a for 24 h (n ¼ 5 patients). To determine the effect of C5a on NFKBIA (IjB-a) protein by Western blotting, tissues were incubated with C5a for 45 min (n ¼ 4 patients). Additional experiments were also performed whereby placenta and fetal membranes were pretreated with 1 or 10 lM PMX53 (AcF-[OP(d-Cha) WR]) [30] or 50 lM BAY 11-7082 for 30 min before the addition of 0.5 lg/ml C5a or 10 lg/ml LPS (from Escherichia coli O26:B6) for 24 h (n ¼ 3-6 patients). After final incubation, tissue and media were collected separately and stored at À808C for further analysis as detailed below.
Western Blotting
Tissue lysates and Western blotting were prepared as previously described [8, 31, 32] . Rabbit polyclonal anti-IjB-a (Santa Cruz Biotechnology) and rabbit polyclonal anti-COX-2 (PTGS2) (Santa Cruz Biotechnology) were used at 1 lg/ml. Forty micrograms of protein was separated on polyacrylamide gels (Bio-Rad Laboratories) and transferred to PVDF. Protein expression was identified by comparison with the mobility of protein standard. Membranes were viewed and analyzed using the Chemi-Doc system (Bio-Rad). Semiquantitative analysis of the relative density of the bands in Western blots was performed using Quantity One 4.2.1 image analysis software (Bio-Rad). Data were corrected for background, normalized to b-actin expression, and expressed as the ratio of the average for the vehicle-treated controls (basal).
Enzyme Immunoassays
After 24 h of incubation, the explant incubation medium was collected, and the release of IL6 and IL8 was performed by sandwich ELISA according to the manufacturers' instructions (Invitrogen). The release of PGE 2 , PGF 2a , and 8-isoprostane into the incubation medium was assayed using a commercially available competitive enzyme immunoassay kit according to the manufacturer's specifications (Kookaburra Kits from Sapphire Bioscience). All data were corrected for total protein and expressed as nanograms per milligram protein.
The protein content of tissue homogenates was determined using BCA protein assay (Pierce), using BSA as a reference standard. The calculated interassay and intra-assay coefficients of variation were all less than 10%.
Gelatin Zymography
MMP2 and MMP9 enzyme activity in conditioned media was analyzed by gelatin zymography as previously described [32] . Gels were viewed and analyzed using the Chemi-Doc system (Bio-Rad). Quantitative analysis of the relative density was performed using Quantity One 4.2.1 image analysis software (Bio-Rad). Data were corrected for background and expressed as ratio of vehicle-treated controls (basal).
Assessment of NFKB p65 DNA Binding Activity NFKB DNA binding in nuclear protein extracts was assessed using a commercially available NFKB p65 Transcription Factor ELISA according to manufacturer's instructions (Cayman Chemical Co.). Data are expressed as absorbance at 450 nm.
Statistical Analysis
Statistical analyses were performed using a commercially available statistical software package (Statgraphics Plus version 3.1; Statistical Graphics Corp.). To determine the effect of C5a on prolabor mediators, data were analyzed by paired sample comparison. For all other comparisons, analysis was performed using a one-way analysis of variance (ANOVA; using LSD correction to discriminate among the means); homogeneity of data was assessed by the Bartlett test, and, when significant, data were logarithmically transformed before further analysis. For Figures 4-7, data were logarithmically transformed to normalize their distribution before further analysis by one-way ANOVA. Statistical significance was ascribed to P value ,0.05. Data was expressed as mean 6 SEM.
RESULTS
Dose Response to Determine Optimal C5a Concentration
An initial dose response was performed to determine the optimal C5a concentration. Human fetal membranes were incubated with 0 (basal), 0.1, 0.25, and 0.5 lg/ml C5a for 24 h, and cytokine concentration in the incubation medium was assayed by ELISA (n ¼ 3 patients with four replicates per FIG. 1. Dose response for C5a on IL8 release. Human fetal membranes were incubated in the absence or presence of 0.1, 0.25, and 0.5 lg/ml C5a for 24 h (n ¼ 3 patients). Each bar represents the mean cytokine release 6 SEM. *P , 0.05 versus 0 lg/ml C5a; P , 0.05 versus 0.5 lg/ml C5a. One-way ANOVA was used to test for significant differences among sample means.
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FIG. 2. C5a induces pro-labor mediators in human placenta and fetal membranes. Human placenta and fetal membranes were incubated in the absence or presence of 0.5 lg/ml C5a for 24 h. A) IL6 and IL8 release; data represent mean cytokine release 6 SEM (n ¼ 5 patients); *P , 0.05 versus basal cytokine release. B) PTGS2 (COX-2) protein expression. PTGS2 protein expression was analyzed by Western blotting and normalized to b-actin. Data are expressed as the ratio of vehicle treated controls (basal) 6 SEM (n ¼ 5 patients); *P , 0.05 versus basal PTGS2 expression. A representative Western blot from two of the five patients analyzed is shown. C) PGE 2 and PGF 2a release; data represent mean prostaglandin release 6 SEM (n ¼ 5 patients); *P , 0.05 versus basal prostaglandin release. D) Secretory pro-MMP2 and pro-MMP9 activity. Data represent mean fold change from basal 6 SEM (n ¼ 5 patients); *P , 0.05 versus basal pro-MMP9 activity. A representative zymogram from two of the five patients analyzed is shown. E) 8-Isoprostane release; data represent mean 8-isoprostane release 6 SEM (n ¼ 5 patients). *P , 0.05 versus basal 8-isoprostane release. For all data, a paired two-tailed t-test was used to assess differences basal and C5a-treated samples.
C5a UPREGULATES PROLABOR MEDIATORS treatment). As shown in Figure 1 , C5a at all concentrations significantly increased IL8 concentrations. There was no difference in response between 0.1 and 0.25 lg/ml C5a; however, C5a at 0.5 lg/ml induced significantly greater IL8 release than 0.1 and 0.25 lg/ml. Similar results were obtained for IL6 (data not shown). For all subsequent experiments, human gestational tissues were incubated in the absence (basal) or presence of 0.5 lg/ml (;60 nM) C5a.
Effect of Human Recombinant C5a on Proinflammatory Cytokines, Prostaglandins, Protease, and 8-Isoprostane Release from Human Placenta and Fetal Membranes Placenta and fetal membranes were incubated in the absence (control) or presence of 0.5 lg/ml human recombinant C5a for 24 h (n ¼ 5 patients). Cytokine and prostaglandin release was measured by ELISA, secretory protease activity by gelatin zymography, and COX expression by Western blotting. As demonstrated in Figure 2A , C5a significantly increased IL6 and IL8 release from human placenta and fetal membranes. Similarly, C5a significantly increased PTGS2 (COX-2) expression (Fig. 2B) , which was associated with an increase in PGE 2 and PGF 2a release (Fig. 2C) . Furthermore, in the presence of C5a, secretory enzyme activity of pro-MMP9 (Fig.  2D ) and 8-isoprostane release (Fig. 2E) were also significantly increased. Given that C5a was able to induce prolabor cytokines in both placenta and fetal membranes, for all subsequent studies, only data for placenta are shown.
C5a Activates NFKB p65 DNA Binding Activity NFKB is a key transcription factor responsible for regulation of inflammation in human gestational tissues [6, 7] . A variety of extracellular signals can activate NFKB through activating the enzyme IjB kinase and subsequent degradation of the NFKBIA (IjB-a) protein. In nongestational tissues, there is some evidence to suggest that C5a regulates inflammation via NFKB [26] [27] [28] . Thus, we next studied the effect of C5a on NFKB activation in human placenta. Human placenta was incubated in the absence (basal) or presence of 0.5 lg/ml recombinant C5a for 45 min, and cytoplasmic NFKBIA (IjB-a) protein expression was analyzed by Western blotting (n ¼ 4 patients). Nuclear NFKB p65 DNA binding activity, as assessed by ELISA, was determined after incubation of placenta with C5a for 24 h (n ¼ 5 patients). As shown in Figure 3A , incubation of human placenta with C5a reduced the levels of IjB-a. Additionally, C5a significantly increased NFKB p65 DNA binding activity (Fig. 3B) .
Effect of the CD88 Antagonist PMX53 on C5a-Induced Prolabor Mediators in Human Placenta
We next sought to determine whether the CD88 antagonist PMX53 could alleviate the proinflammatory effects of C5a. To address this, we conducted experiments in which placenta was preincubated for 30 min with PMX53 (1 and 10 lM) before stimulation with 0.5 lg/ml C5a for 24 h (n ¼ 4 patients). PMX53 at both 1 and 10 lM significantly attenuated C5a-induced cytokine release (Fig. 4A ) and 8-isoprostane release (Fig. 4D ). PMX53 at 10 lM significantly decreased C5a-induced prostaglandin (Fig. 4B) , pro-MMP9 release (Fig. 4C) , and NFKB p65 DNA binding activity (Fig. 4E ).
C5a Upregulates Prolabor Mediators by NFKB
To address the question of whether C5a-induced inflammation in placenta was NFKB dependent, we conducted experiments in which placenta was preincubated with an NFKB inhibitor BAY 11-7082 (which blocks NFKBIA [IjBa] phosphorylation) before stimulation with C5a (n ¼ 4 patients). Incubation of human placenta with 50 lM BAY 11-7082 significantly attenuated C5a-induced cytokine release (Fig. 5A ), prostaglandin release (Fig. 5B) , secretory MMP9 activity (Fig. 5C) , and 8-isoprostane release (Fig. 5D) .
Effect of CD88 Antagonists PMX53 on LPS-Induced Proinflammatory Mediators in Human Gestational Tissues
Previous studies have shown that PMX53 can reduce LPSinduced inflammation in vivo [29] . Thus, the next aim was to determine the effect of CD88 blockade, using the CD88 antagonist PMX53, on LPS-induced inflammation in human gestational tissues in vitro. Human placenta and fetal membranes were incubated in the absence (control) and presence of bacterial endotoxin LPS with and without 1 or 10 lM PMX53 for 24 h (n ¼ 4 patients). Figure 6 demonstrates the effect of 10 lM PMX53 on LPS-induced inflammation in human placenta; similar results were obtained for 1 lM PMX53 (data not shown) and for fetal membranes (data not shown). As expected, LPS significantly induced IL6 (Fig. 6A) , PGE 2 (Fig. 6B) , and 8-isoprostane ( Fig. 6C) release; however, there was no effect of CD88 antagonist on LPS-induced prolabor mediators (Fig. 6 ). Similar data were obtained for IL8, PGF 2a , and pro-MMP9 (data not shown) and fetal membranes (data not shown).
FIG. 3. C5a activates the NFKB pathway. A)
Human placenta was incubated in the absence or presence of 0.5 lg/ml C5a for 45 min (n ¼ 4 patients). NFKBIA (IjB-a) protein expression was analyzed by Western blotting. Two patient samples are shown. Similar results were obtained for another two patients. B) Human placenta was incubated in the absence or presence of 0.5 lg/ml C5a for 24 h (n ¼ 4 patients). NFKB p65 DNA binding activity was assayed using a transcription factor ELISA. Each bar represents the mean absorbance 6 SEM (n ¼ 5 placentas). *P , 0.05 versus basal NFKB p65 activity. For all data, a paired two-tailed t-test was used to assess differences basal and C5a-treated samples.
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FIG. 4. C5a induces prolabor mediators via complement receptor CD88. Human placenta was preincubated with 1 and 10 lM PMX53 for 30 min prior to the addition of 0.5 lg/ml C5a for 24 h (n ¼ 4 patients). A) IL6 and IL8 release; data represent mean cytokine release 6 SEM; *P , 0.05 versus C5a-induced cytokine release. B) PGE 2 and PGF 2a release; data represent mean prostaglandin release 6 SEM; *P , 0.05 versus C5a-induced prostaglandin release. C) Secretory pro-MMP2 and pro-MMP9 activity; data represent mean fold change from basal 6 SEM; *P , 0.05 versus C5a-induced pro-MMP9 activity. A representative zymogram experiment from one of the four patients analyzed is shown. D) 8-Isoprostane release; data represent mean 8-isoprostane release 6 SEM. *P , 0.05 versus C5a-induced 8-isoprostane release. E) NFKB p65 DNA binding activity; each bar represents the mean absorbance 6 SEM; P , 0.05 versus C5a-induced NFKB p65 activity. One-way ANOVA was used to test for significant differences among sample means.
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FIG. 5. C5a induces inflammation via NFKB. Human placenta was preincubated with 50 lM BAY 11-0782 for 30 min prior to the addition of 0.5 lg/ml C5a for 24 h (n ¼ 4 patients). A) IL6 and IL8 release; data represent mean cytokine release 6 SEM; *P , 0.05 versus C5a-induced cytokine release. B) PGE 2 and PGF 2a release; data represent mean prostaglandin release 6 SEM; *P , 0.05 versus C5a-induced prostaglandin FIG. 6. LPS does not induce prolabor mediators via the complement receptor CD88. Human placenta was preincubated with 10 lM PMX53 for 30 min prior to the addition of 10 lg/ml LPS for 24 h (n ¼ 4 patients). A) IL6 release; data represent mean release 6 SEM; *P , 0.05 versus LPSinduced cytokine release. B) PGE 2 release; data represent mean release 6 SEM; *P , 0.05 versus LPS-induced PGE 2 release. C) 8-Isoprostane release; data represent mean release 6 SEM; *P , 0.05 versus LPSinduced 8-isoprostane release. For all data, one way ANOVA was used to test for significant differences among sample means.
3 release. C) Secretory pro-MMP2 and pro-MMP9 activity; data represent mean fold change from basal 6 SEM (n ¼ 4 patients); *P , 0.05 versus C5a-induced pro-MMP9 activity. A representative zymogram experiment from one of the four patients analyzed is shown. D) 8-Isoprostane release; data represent mean 8-isoprostane release 6 SEM. *P , 0.05 versus C5a-induced 8-isoprostane release. For all data, one-way ANOVA was used to test for significant differences among sample means.
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C5a Does Not Augment LPS-Induced Proinflammatory Mediators in Human Gestational Tissues
C5a can enhance inflammation in the copresence of LPS [33] [34] [35] [36] . In order to determine whether C5a could augment an inflammatory response, human placenta and fetal membranes were each stimulated with 10 lg/ml LPS alone or together with 0.5 lg/ml C5a (n ¼ 4 patients). As expected, LPS significantly induced IL6 (Fig. 7A), PGE 2 (Fig. 7B) , and 8-isoprostane ( Fig.   7C ) release; however, there was no augmentation of any LPSinduced prolabor effects by C5a (Fig. 7) . Similar data were also obtained for IL8, PGF 2a , and pro-MMP9 (data not shown) and fetal membranes (data not shown).
DISCUSSION
In this study, we found that C5a is an activator of key mediators of the terminal processes of human labor and delivery. That is, C5a induced an increase in cytokine, prostaglandin, pro-MMP9, and 8-isoprostane release from human gestational tissues. This effect was mediated predominantly by the C5AR termed CD88, as the specific CD88 antagonist PMX53 attenuated C5a-induced prolabor mediators. We also found that C5a induced NFKB activation, an effect that could be abolished with PMX53. The prolabor actions of C5a appear to be downstream of NFKB, as the NFKB inhibitor BAY 11-7082 also abolished C5a-induced inflammation.
Under normal physiological conditions, activation of complement triggers an inflammatory cascade resulting in immune cell activation and the rapid opsonization and destruction of foreign pathogens [13] . However, excessive complement activation-and thus production of C5a-contributes to the progression of numerous disease states, including sepsis, rheumatoid arthritis, inflammatory bowel disease, ischemia reperfusion injuries, and neurodegenerative diseases [37] [38] [39] [40] [41] . Similarly, women with preterm delivery and intraamniotic infection have increased plasma C5a levels [10] , tempting the hypothesis that C5a plays a role in the pathogenesis of preterm labor. It is of note that a recent study in mice found that the release of MMPs in preterm delivery is triggered by C5a [42] . In addition, this study also reported increased release of MMP9 in response to C5a in cervical macrophages in vitro. Our studies demonstrate that excessive circulating C5a contributes to the release of proinflammatory cytokines, phospholipid-derived mediators, and ECM remodeling enzymes from human gestational tissues. Collectively, these mediators regulate the terminal pathways of human labor and delivery; namely, uterine contractility, cervical dilation, and rupture of membranes.
In this study, our data support a role for CD88 in the prolabor effects of C5a. We used the selective C5AR inhibitor, PMX53, which only blocks the classical G protein-coupled C5a receptor, CD88 [25] , to demonstrate the mechanism by which C5a produces its proinflammatory and prolabor outputs in human placenta. We found that pretreatment with the CD88 antagonist PMX53 was associated with a significant attenuation of C5a-induced expression of proinflammatory cytokines, prostaglandins, ROS, and pro-MMP9 activity. However, it is of note that PMX53 did not completely block all IL6 and IL8 release. There are two C5a receptors, the classical proinflammatory one (CD88) and a second, enigmatic, non-G protein coupled one (C5L2; official symbol GPR77). Thus, it is also possible that C5a may be signaling via C5L2, and such signaling for release of certain proinflammatory cytokines in experimental sepsis has been reported [43] .
NFKB regulates the multiple terminal effector pathways involved in spontaneous-onset labor and delivery [6, 7] . In response to various stimuli, NFKBIA (IjB-a) is rapidly degraded to allow NFKB nuclear translocation and NFKB target gene transcription. Likewise, in this study, C5a activates NFKB in placenta, as evident by both increased NFKBIA (IjB-a) degradation and NFKB p65 DNA activity in response to human recombinant C5a. Furthermore, the NFKB inhibitor BAY 11-7082 attenuated C5a-induced inflammation, indicating that NFKB-dependent upregulation of prolabor gene FIG. 7. C5a does not augment LPS-induced pro-labor mediators. Human placenta was incubated with 10 lg/ml LPS in the absence or presence of 0.5 lg/ml C5a for 24 h (n ¼ 4 patients). A) IL6 release; data represent mean release 6 SEM; *P , 0.05 versus LPS-induced cytokine release. B) PGE 2 release; data represent mean release 6 SEM; *P , 0.05 versus LPSinduced PGE 2 release. C) 8-Isoprostane release; data represent mean release 6 SEM; *P , 0.05 versus LPS-induced 8-isoprostane release. For all data, one way ANOVA was used to test for significant differences among sample means.
C5a UPREGULATES PROLABOR MEDIATORS transcription plays a major role in the C5a-mediated inflammatory response. The findings of this current study are in keeping with our previously published studies that demonstrate cytokine, prostaglandin, and MMP9 regulation by NFKB in human gestational tissues [6-8, 32, 44, 45] . Similarly, other studies in nongestational tissues have shown an important role for NFKB in the regulation of C5a-mediated functions [26, 27, 46] . In this study, we also demonstrate that the CD88 antagonist PMX53 inhibited C5a-induced NFKB p65 activity. Collectively, our data suggest that C5a binds to its receptor CD88 to upregulate proinflammatory and prolabor gene expression by NFKB.
Sepsis involves the circulation of LPS, which subsequently activated complement and leads to the generation of C5a. LPS also binds to TLR4, whereas C5a binds to the C5ARs; CD88, and C5L2 (GPR77). CD88 was shown to be a regulator of TLR4-mediated inflammation in mice [14, 29] , and C5a can enhance inflammation in the copresence of LPS [33] [34] [35] [36] . However, in this study, we demonstrated no effect of C5a or of the CD88 antagonist PMX53 on LPS-induced inflammation in human gestational tissues. This suggests that LPS activates prolabor mediators in a CD88-independent manner and that any C5a produced by placental tissues is insufficient to magnify the effect of the maximally effective concentration of LPS used in our study. Nevertheless, our data demonstrate that both LPS and C5a can increase prolabor mediators from human gestational tissues. Although their actions in this system are apparently elicited via different cell surface receptors, both mediate inflammation via activation of NFKB signaling. However, our results show unequivocally that PMX53 blocks C5a-induced mediators but in the same human reproductive tissues are without effect on LPS-induced mediators.
In this study, we show that interaction of C5a, with its receptor, CD88, results in inflammation and enhanced release of cytokines, prostaglandins, proteases, and ROS. These prolabor mediators are involved in the terminal processes of labor and delivery. Of note, we found that C5a increased NFKB activity, an effect that was diminished by pretreatment with the CD88 antagonist PMX53. Collectively, our data suggest that, in human placenta, C5a binds to its receptor CD88 to upregulate proinflammatory and prolabor gene expression by NFKB. This has important implications, as a previous study reported that increased circulating C5a levels are associated with infection associated preterm birth [10] , and in mice models of preterm birth, NFKB is increased in gestational tissues [47] . Whether C5a or CD88 inhibitors will be beneficial in the management of preterm labor is not known; however, blockade of C5a-CD88 signaling with antibodies or specific antagonists such as PMX53 seems to be an especially effective potential therapeutic intervention during development of experimental sepsis [48, 49] . Further in vivo studies are required to determine if blocking C5a-CD88 signaling can delay preterm delivery.
